FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247473354> ?p ?o ?g. }

• W2247473354 abstract "7072 Background: Chronic myeloid leukemia (CML) with introduction of imatinib has been transformed into a chronic illness. The options of treatment in a patient less than 35 years include imatinib or allogenic stem cell transplantation. Hence we studied this unique subset to look at the response rates, adverse effects, progression free survival, and overall survival with imatinib mesylate. Methods: 477 patients with Philadelphia positive CML in chronic phase were retrospectively analyzed from January 2002 to December 2007 at Cancer Institute (WIA), Chennai, India. Standard criteria were used for response evaluation and adverse effects. Results: A total of 248 young CML patients with age less than 35 years (51.9%) were diagnosed in chronic phase. The median age of study population was 27 years (4–35). The male to female ratio was 1.9: 1. Risk stratification was done using Sokal index and were classified into low (32.3%), intermediate (50.4%), and high (17.3%). All patients received imatinib 400 mg as the initial dose. Complete hematological remission (CHR) was seen in 96.7%.Cytogenetic (FISH) and molecular (RTPCR) monitoring was possible in 53.2% and 17.3%, respectively. 72% of the patients had major cytogenetic response. Major molecular response was seen in 34.8% while complete molecular response occurred in 23.2% of the patients. Primary and secondary imatinib failure was seen in 3.1% and 16.9%, respectively. 6.7% had grade 3 and grade 4 hematological toxicities. The other common non hematological toxicities included pedal edema (13.7%), hypo or hyper pigmentation (60.0%), hyalgia (14.5%), diarrhea (1.6%), and liver dysfunction (1.6%). None of the patients discontinued imatinib due to toxicities. The 3-year DFS and OS was 86.2% and 89.5%, respectively. Patients with male sex (p = 0.04), spleen > 8 cm (p = 0.02), high sokal index (p = 0.02), and loss of CHR (p < 0.001) were associated with poor outcome. Conclusions: Imatinib in young patients have an excellent tolerance and response. A small subset does not respond to therapy or develop resistance during treatment. Hence it is essential to identify these poor responders and to offer stem cell transplantation at the earliest. No significant financial relationships to disclose." @default.
• W2247473354 created "2016-06-24" @default.
• W2247473354 creator A5018712940 @default.
• W2247473354 creator A5020305020 @default.
• W2247473354 creator A5026437364 @default.
• W2247473354 creator A5034857455 @default.
• W2247473354 creator A5057564869 @default.
• W2247473354 creator A5067093967 @default.
• W2247473354 creator A5076600103 @default.
• W2247473354 creator A5079230950 @default.
• W2247473354 date "2009-05-20" @default.
• W2247473354 modified "2023-10-01" @default.
• W2247473354 title "Imatinib mesylate experience of young patients with chronic myeloid leukemia in chronic phase—Care to cure" @default.
• W2247473354 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.7072" @default.
• W2247473354 hasPublicationYear "2009" @default.
• W2247473354 type Work @default.
• W2247473354 sameAs 2247473354 @default.
• W2247473354 citedByCount "0" @default.
• W2247473354 crossrefType "journal-article" @default.
• W2247473354 hasAuthorship W2247473354A5018712940 @default.
• W2247473354 hasAuthorship W2247473354A5020305020 @default.
• W2247473354 hasAuthorship W2247473354A5026437364 @default.
• W2247473354 hasAuthorship W2247473354A5034857455 @default.
• W2247473354 hasAuthorship W2247473354A5057564869 @default.
• W2247473354 hasAuthorship W2247473354A5067093967 @default.
• W2247473354 hasAuthorship W2247473354A5076600103 @default.
• W2247473354 hasAuthorship W2247473354A5079230950 @default.
• W2247473354 hasConcept C126322002 @default.
• W2247473354 hasConcept C143998085 @default.
• W2247473354 hasConcept C2777583451 @default.
• W2247473354 hasConcept C2778729363 @default.
• W2247473354 hasConcept C3019892230 @default.
• W2247473354 hasConcept C71924100 @default.
• W2247473354 hasConceptScore W2247473354C126322002 @default.
• W2247473354 hasConceptScore W2247473354C143998085 @default.
• W2247473354 hasConceptScore W2247473354C2777583451 @default.
• W2247473354 hasConceptScore W2247473354C2778729363 @default.
• W2247473354 hasConceptScore W2247473354C3019892230 @default.
• W2247473354 hasConceptScore W2247473354C71924100 @default.
• W2247473354 hasLocation W22474733541 @default.
• W2247473354 hasOpenAccess W2247473354 @default.
• W2247473354 hasPrimaryLocation W22474733541 @default.
• W2247473354 hasRelatedWork W1969599745 @default.
• W2247473354 hasRelatedWork W2008119277 @default.
• W2247473354 hasRelatedWork W2087133875 @default.
• W2247473354 hasRelatedWork W2092370059 @default.
• W2247473354 hasRelatedWork W2121321278 @default.
• W2247473354 hasRelatedWork W2145721329 @default.
• W2247473354 hasRelatedWork W2167877833 @default.
• W2247473354 hasRelatedWork W2268034767 @default.
• W2247473354 hasRelatedWork W2359405586 @default.
• W2247473354 hasRelatedWork W2391998668 @default.
• W2247473354 hasRelatedWork W2444430071 @default.
• W2247473354 hasRelatedWork W2472410533 @default.
• W2247473354 hasRelatedWork W2575963273 @default.
• W2247473354 hasRelatedWork W2597424333 @default.
• W2247473354 hasRelatedWork W2802370174 @default.
• W2247473354 hasRelatedWork W2937213107 @default.
• W2247473354 hasRelatedWork W3006930052 @default.
• W2247473354 hasRelatedWork W3036609897 @default.
• W2247473354 hasRelatedWork W3102322285 @default.
• W2247473354 hasRelatedWork W3176623981 @default.
• W2247473354 isParatext "false" @default.
• W2247473354 isRetracted "false" @default.
• W2247473354 magId "2247473354" @default.
• W2247473354 workType "article" @default.